Publications
June 29, 2021
The TIGIT Pathway, PVRIG, a Novel Pathway Member, Targets for Cancer Immunotherapy: A Deep Dive
Eran Ophir, VP Research and Drug Discover June 2021.
June 8, 2021
COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716)
Daniel A. Vaena, et al, ASCO Annual Meeting
April 13, 2021
Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis
Zoya Alteber, Maya F Kotturi, Sarah Whelan, et al.
November 5, 2020
PVRIG is a novel NK cell immune checkpoint receptor in acute myeloid leukemia
Jessica Li, et al, Haematologica
October 27, 2020
Rationalizing Combination Strategies to Maximize Clinical Response as Novel ICI Therapies Emerge
Eran Ophir, TIGIT Therapies Digital Summit
April 27, 2020
COM701 Demonstrates Antitumor Activity as Monotherapy and in Combination with Nivolumab in Patients with Advanced Malignancies
Ryan Sullivan, et al, AACR Annual Meeting
April 20, 2020
Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2)
Julia Huetter, et al, Cancer Immunology Research
February 6, 2020
A Phase 1 Study Evaluating COM701 Monotherapy and in Combination with Nivolumab in Patients with Advanced Solid Malignancies
RJ Sullivan, et al, ASCO-SITC Clinical Immuno-Oncology Symposium
December 10, 2019
Activation of Human NK Cells Modulates Expression of the Inhibitory Reception PVRIG
Jessica Li, el al, The Australian and New Zealand Society for Immunology (ASI) Annual Meeting
November 9, 2019
Phase 1 Study of COM701 Monotherapy and in Combination with Nivolumab in Patients with Advanced Solid Tumors
E. Ileana Dumbrava, et al, SITC Annual Meeting